We are live on ! Find out more
AVAI

Atlas Venture Associates IX Portfolio holdings

AUM $11.8M
1-Year Est. Return 58.35%
This Fund
S&P 500
This Quarter Est. Return
-11.08%
1 Year Est. Return
-58.35%
3 Year Est. Return
-89.8%
5 Year Est. Return
-87.69%
10 Year Est. Return
–
AUM
$18.3M
AUM Growth
-$3.03M
Cap. Flow
-$40.5K
Cap. Flow %
-0.22%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
2
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
SPRO icon
Spero Therapeutics
SPRO
+$40.5K
2
FIRY
Firy Inc
FIRY
+$12

Sector Composition

Rank Sector Weight
1 Communication Services 66.77%
2 Healthcare 33.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FIRY
1
Firy Inc
FIRY
$146M
$10.4M 57.04%
1,145,492
-1
-0% -$12
SURF
2
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$2.56M 14.02%
2,945,453
– –
SPRO icon
3
Spero Therapeutics
SPRO
$71.2M
$1.96M 10.74%
1,353,303
-23,665
-2% -$40.5K
SNAP icon
4
Snap
SNAP
$9.74B
$1.78M 9.73%
150,160
– –
SYBX
5
DELISTED
Synlogic
SYBX
$1.14M 6.24%
176,798
– –
NTLA icon
6
Intellia Therapeutics
NTLA
$1.58B
$408K 2.23%
10,000
– –

Similar funds

EEPIS
Evolution Equity Partners II SARL Luxembourg $11.8M AUM 63.6% 1-Year Est. Return
LM
Lockheed Martin Bethesda, Maryland $12.1M AUM 46.13% 1-Year Est. Return
HMP9
Highland Management Partners 9 Cambridge, Massachusetts $12.6M AUM 85.13% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
AEM
ACON Equity Management Washington, District of Columbia $13.8M AUM 62.17% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return
AR
Acacia Research New York $14.1M AUM 50.98% 1-Year Est. Return
MM
Malka Meyer $8.77M AUM 64.77% 1-Year Est. Return

Atlas Venture Associates IX's Q2 2023 Portfolio in Review

As of Q2 2023, Atlas Venture Associates IX held 6 positions worth $18.3M, down 14% from $21.3M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2023: portfolio turnover was 0%. Atlas Venture Associates IX opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Communication Services at 67% of assets, down from 71% a quarter earlier, followed by Healthcare.

  • Atlas Venture Associates IX's biggest Q2 2023 reduction was Spero Therapeutics, cutting an estimated $40.5K.
  • Atlas Venture Associates IX's ten largest holdings make up 100% of its $18.3M portfolio in Q2 2023.
  • Atlas Venture Associates IX opened 0 new positions and closed 0 in Q2 2023.
  • Atlas Venture Associates IX's portfolio value fell 14% quarter-over-quarter to $18.3M.

Based on Atlas Venture Associates IX's 13F filing for Q2 2023, filed 8 Aug 2023.